Becton, Dickinson and Company – NYSE:BDX
Becton, Dickinson and Company stock price today
$198.05
-30.43
-13.32%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 1 hour
Becton, Dickinson and Company stock price monthly change
-0.27%
month
Becton, Dickinson and Company stock price quarterly change
-0.27%
quarter
Becton, Dickinson and Company stock price yearly change
-5.78%
year
Becton, Dickinson and Company key metrics
Market Cap | 65.86B |
Enterprise value | 84.65B |
P/E | 38.33 |
EV/Sales | 4.19 |
EV/EBITDA | 19.87 |
Price/Sales | 3.28 |
Price/Book | 1.15 |
PEG ratio | 1.12 |
EPS | 5.13 |
Revenue | 19.83B |
EBITDA | 4.92B |
Income | 1.51B |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 8.55% |
Oper. margin | 13.08% |
Gross margin | 45.22% |
EBIT margin | 13.08% |
EBITDA margin | 24.86% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeBecton, Dickinson and Company stock price history
Becton, Dickinson and Company stock forecast
Becton, Dickinson and Company financial statements
| Mar 2023 | 4.82B | 460M | 9.54% |
|---|---|---|---|
| Jun 2023 | 4.87B | 407M | 8.34% |
| Sep 2023 | 5.08B | 108M | 2.12% |
| Mar 2024 | 5.04B | 537M | 10.64% |
| Mar 2024 | 5.04B | 537M | 10.64% |
|---|---|---|---|
| Sep 2025 | 5.68B | 1.19B | 20.93% |
| Oct 2025 | 5.68B | 1.18B | 20.82% |
| Dec 2025 | 5.27B | 0 |
Analysts Price target
Financials & Ratios estimates
1.70%
Yield TTM
| Payout ratio | 63.73% |
|---|
| 2020 | 1.62% |
|---|---|
| 2021 | 1.51% |
| 2022 | 1.7% |
| 2023 | 1.51% |
| 2024 | 1.57% |
| Mar 2023 | 54394000000 | 28.70B | 52.77% |
|---|---|---|---|
| Jun 2023 | 53017000000 | 27.08B | 51.08% |
| Sep 2023 | 52780000000 | 26.98B | 51.13% |
| Mar 2024 | 54157000000 | 28.50B | 52.64% |
| Mar 2023 | 184M | -233M | 1.36B |
|---|---|---|---|
| Jun 2023 | 1.08B | -329M | -1.79B |
| Sep 2023 | 1.32B | 137M | -998M |
| Mar 2024 | 515M | -1.05B | 1.70B |
Becton, Dickinson and Company alternative data
| Sep 2023 | 77,000 |
|---|---|
| Oct 2023 | 77,000 |
| Nov 2023 | 77,000 |
| Dec 2023 | 73,000 |
| Jan 2024 | 73,000 |
| Feb 2024 | 73,000 |
| Mar 2024 | 73,000 |
| Apr 2024 | 73,000 |
| May 2024 | 73,000 |
| Jun 2024 | 70,000 |
| Jul 2024 | 70,000 |
Becton, Dickinson and Company other data
81.98%
-1.91%
of BDX is owned by hedge funds
1.51K
-7
240.92M
-10.22M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Mar 2024 | 0 | 282 |
| Apr 2024 | 0 | 1715 |
| May 2024 | 0 | 6600 |
| Jun 2024 | 0 | 300 |
| Dec 2024 | 0 | 10459 |
| Patent |
|---|
Application Filling date: 4 Mar 2022 Issue date: 8 Sep 2022 |
Application Filling date: 23 Jul 2020 Issue date: 8 Sep 2022 |
Application Filling date: 16 May 2022 Issue date: 1 Sep 2022 |
Application Filling date: 8 Jul 2020 Issue date: 1 Sep 2022 |
Application Filling date: 16 May 2022 Issue date: 25 Aug 2022 |
Application Filling date: 10 May 2022 Issue date: 25 Aug 2022 |
Application Filling date: 25 Feb 2022 Issue date: 25 Aug 2022 |
Application Filling date: 9 May 2022 Issue date: 18 Aug 2022 |
Application Filling date: 29 Apr 2022 Issue date: 11 Aug 2022 |
Application Filling date: 27 Apr 2022 Issue date: 11 Aug 2022 |
| Quarter | Transcript |
|---|---|
| Q2 2024 2 May 2024 | Q2 2024 Earnings Call Transcript |
| Q1 2024 1 Feb 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 9 Nov 2023 | Q4 2023 Earnings Call Transcript |
| Q3 2023 3 Aug 2023 | Q3 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Mr. Thomas E. Polen Jr. (1973) Pres, Chief Executive Officer & Chairman | $3,690,000 |
Mr. Alberto Mas (1961) Executive Vice President & Pres of the Medical Segment | $1,580,000 |
| Mr. Samrat S. Khichi Esq. (1967) Executive Vice President of Corporation Devel., Public Policy & Regulatory Affairs and Gen. Counsel | $1,460,000 |
| Mr. Simon D. Campion (1971) Executive Vice President & Pres of Interventional Segment | $1,310,000 |
| Mr. Christopher DelOrefice (1971) Executive Vice President & Chief Financial Officer | $511,650 |
Boston Scientific Corporation: Solid Financials And Upward Continuation
Merit Medical: Undervalued With Multiple Growth Drivers In Play
Becton, Dickinson: 4 Reasons To Buy This Growth At A Reasonable Price Play
Teleflex Shares Hit Hard As Growth Concerns Stack Up
Becton, Dickinson Stock Is A Hold, Here's Why
Becton, Dickinson: Ahead Of Schedule, Undervalued, And With Some Positive Drivers
Embecta: Mammoth Effort Needed To Get Investors Over The Line, Reiterate Hold
Becton, Dickinson and Company: Still Not Very Healthy
Becton, Dickinson and Company: This Serial-Acquirer Is A Buy
-
What's the price of Becton, Dickinson and Company stock today?
One share of Becton, Dickinson and Company stock can currently be purchased for approximately $198.05.
-
When is Becton, Dickinson and Company's next earnings date?
Unfortunately, Becton, Dickinson and Company's (BDX) next earnings date is currently unknown.
-
Does Becton, Dickinson and Company pay dividends?
Yes, Becton, Dickinson and Company pays dividends and its trailing 12-month yield is 1.7% with 64% payout ratio. The last Becton, Dickinson and Company stock dividend of $0.87 was paid on 31 Dec 2021.
-
How much money does Becton, Dickinson and Company make?
Becton, Dickinson and Company has a market capitalization of 65.86B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 4.16% to 20.18B US dollars.
-
What is Becton, Dickinson and Company's stock symbol?
Becton, Dickinson and Company is traded on the NYSE under the ticker symbol "BDX".
-
What is Becton, Dickinson and Company's primary industry?
Company operates in the Healthcare sector and Medical - Instruments & Supplies industry.
-
How do i buy shares of Becton, Dickinson and Company?
Shares of Becton, Dickinson and Company can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Becton, Dickinson and Company's key executives?
Becton, Dickinson and Company's management team includes the following people:
- Mr. Thomas E. Polen Jr. Pres, Chief Executive Officer & Chairman(age: 52, pay: $3,690,000)
- Mr. Alberto Mas Executive Vice President & Pres of the Medical Segment(age: 64, pay: $1,580,000)
- Mr. Samrat S. Khichi Esq. Executive Vice President of Corporation Devel., Public Policy & Regulatory Affairs and Gen. Counsel(age: 58, pay: $1,460,000)
- Mr. Simon D. Campion Executive Vice President & Pres of Interventional Segment(age: 54, pay: $1,310,000)
- Mr. Christopher DelOrefice Executive Vice President & Chief Financial Officer(age: 54, pay: $511,650)
-
How many employees does Becton, Dickinson and Company have?
As Jul 2024, Becton, Dickinson and Company employs 70,000 workers, which is 4% less then previous quarter.
-
When Becton, Dickinson and Company went public?
Becton, Dickinson and Company is publicly traded company for more then 52 years since IPO on 21 Feb 1973.
-
What is Becton, Dickinson and Company's official website?
The official website for Becton, Dickinson and Company is bd.com.
-
Where are Becton, Dickinson and Company's headquarters?
Becton, Dickinson and Company is headquartered at 1 Becton Drive, Franklin Lakes, NJ.
-
How can i contact Becton, Dickinson and Company?
Becton, Dickinson and Company's mailing address is 1 Becton Drive, Franklin Lakes, NJ and company can be reached via phone at +20 18476800.
Becton, Dickinson and Company company profile:
Becton, Dickinson and Company
bd.comExchange:
NYSE
Full time employees:
70,000
Industry:
Medical - Instruments & Supplies
Sector:
Healthcare
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.
1 Becton Drive
Franklin Lakes, NJ 07417-1880
Franklin Lakes, NJ 07417-1880
CIK: 0000010795
ISIN: US0758871091
CUSIP: 075887109
